We can make gout management more successful now
- PMID: 18349746
- DOI: 10.1097/BOR.0b013e3282f54d03
We can make gout management more successful now
Abstract
Purpose of review: The purpose of this editorial review is to identify and comment on factors contributing to the current less-than-optimal state of gout management and to emphasize immediate opportunities to improve management practices affecting many patients with gout.
Recent findings: Numerous publications document deficits in the current management and clinical outcomes of gout despite detailed understanding of the pathogenesis and pathophysiology of the disorder, the ability to establish the diagnosis with certainty, and the likely effectiveness, for most patients, of available lifestyle and pharmacological interventions. Among impediments to successful gout management are diagnostic inaccuracy; a paucity of validated management recommendations to guide care providers; incomplete patient education about gout and the aims and modalities of management; suboptimal patient adherence, even to demonstrably effective therapeutic recommendations; comorbidities and drug interferences that complicate treatment of gout; patient groups at special risk for progression to chronic tophaceous gout; and limited urate-lowering alternatives.
Summary: Recent publication of evidence-based recommendations for the diagnosis and management of gout and the impending availability of new urate-lowering agents suggest that this is an opportune time to initiate professional and patient education efforts toward improved management of this increasingly common disorder.
Similar articles
-
A survey of the management of gout in primary care.Ir Med J. 2008 May;101(5):147-9. Ir Med J. 2008. PMID: 18624262
-
The management of gout at an academic healthcare center in Beijing: a physician survey.J Rheumatol. 2006 Oct;33(10):2041-9. J Rheumatol. 2006. PMID: 17014019
-
An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study.J Clin Rheumatol. 2011 Oct;17(7):349-55. doi: 10.1097/RHU.0b013e3182314d40. J Clin Rheumatol. 2011. PMID: 21946457
-
Gout: can we create an evidence-based systematic approach to diagnosis and management?Best Pract Res Clin Rheumatol. 2006 Aug;20(4):673-84. doi: 10.1016/j.berh.2006.05.006. Best Pract Res Clin Rheumatol. 2006. PMID: 16979531 Review.
-
A roadmap for education to improve the quality of care in gout.Curr Opin Rheumatol. 2010 Mar;22(2):173-80. doi: 10.1097/BOR.0b013e328335eee3. Curr Opin Rheumatol. 2010. PMID: 20051863 Review.
Cited by
-
A qualitative and quantitative analysis of the characteristics of gout patient education resources.Clin Rheumatol. 2013 Jun;32(6):771-8. doi: 10.1007/s10067-013-2168-8. Epub 2013 Jan 16. Clin Rheumatol. 2013. PMID: 23322247
-
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.Br J Clin Pharmacol. 2012 Aug;74(2):327-35. doi: 10.1111/j.1365-2125.2012.04182.x. Br J Clin Pharmacol. 2012. PMID: 22242967 Free PMC article. Clinical Trial.
-
A patient-centered gout information value chain: a scoping review.Patient Educ Couns. 2022 Jan;105(1):30-43. doi: 10.1016/j.pec.2021.06.007. Epub 2021 Jun 8. Patient Educ Couns. 2022. PMID: 34120817 Free PMC article.
-
African American patients with gout: efficacy and safety of febuxostat vs allopurinol.BMC Musculoskelet Disord. 2012 Feb 9;13:15. doi: 10.1186/1471-2474-13-15. BMC Musculoskelet Disord. 2012. PMID: 22316106 Free PMC article. Clinical Trial.
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6. Arthritis Res Ther. 2010. PMID: 20370912 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials